DGAP-Ad-hoc: aap Implantate AG / Key word(s): Change in Forecast/Quarter Results
Publication of inside information pursuant to Art. 17 MAR
The Management Board of aap Implantate AG ("aap" or the "Company") is issuing an update for the second quarter of 2022 and revising its guidance for the financial year 2022 after macroeconomic conditions have not improved in the second quarter of 2022 and the general market environment in the markets relevant for aap is no longer expected to recover significantly in the short term. The main reasons for this are the persisting pandemic COVID‑19 situation, related bottlenecks in hospitals and also the increasing but still too low mobility and the changed mobility behavior of the population, which is reflected in lower case numbers compared to the pre‑COVID‑19 level. In addition, the ongoing war in Ukraine, the dynamic pressure on global supply chains that can be observed, and the general inflationary environment are generally affecting business development, which is reflected, for example, in the noticeable delayed execution of new customer contracts despite a well‑filled pipeline or in the significantly reduced willingness of aap's existing distribution partners to invest in market expansion.
The company's previous outlook for the full year 2022 from early May took into account the challenges, but also the first signs of a possible recovery. Management now expects macroeconomic challenges to last longer and be more intense than previously anticipated.
Based on preliminary figures, aap achieved sales of around EUR 2.7 million in the second quarter of 2022, which together with the sales of the first quarter results in a sales value of around EUR 5.6 million for the first half of the year. This figure is slightly below the previous year's figure (H1/2021: EUR 6.0 million) and below the expected sales level for the first half of the year based on the original sales guidance for the full year 2022 of EUR 14.0 million to EUR 16.0 million and assuming a similar distribution of sales over the individual quarters as in the previous fiscal year. According to preliminary calculations, EBITDA for the second quarter is around EUR ‑0.2 million, which together with the figure for the first quarter results in EBITDA for the first half of the year of around EUR ‑0.7 million. EBITDA for the first half of the year is thus within the expected range based on the original guidance for the full year 2022 (EUR ‑1.7 million to EUR ‑0.5 million). EBITDA in the second quarter was positively influenced by non‑recurring effects (mainly income from the COVID 19 support program Überbrückungshilfe IV and the reversal of provisions and accruals) amounting to around EUR 0.3 million.
As the company no longer assumes the general market sentiment in the markets relevant for aap to recover significantly in the short term, it is updating its guidance for the financial year 2022. The Management Board now expects a sales level of EUR 11.5 million to EUR 13.5 million (previously: EUR 14.0 million to EUR 16.0 million) and EBITDA of EUR ‑2.0 million to EUR ‑1.1 million (previously: EUR ‑1.7 million to EUR ‑0.5 million) for the financial year 2022.
28-Jul-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Company:||aap Implantate AG|
|Phone:||+49 (0) 30 75 01 90|
|Fax:||+49 (0) 30 75 01 91 11|
|Listed:||Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1408515|
|End of Announcement||DGAP News Service|
1408515 28-Jul-2022 CET/CEST